Tropomyosins: potential biomarkers for Urothelial Bladder Cancer

Nada Humayun-Zakaria, Roland Arnold, Anshita Goel, Douglas Ward, Stuart Savill, Richard Bryan

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
154 Downloads (Pure)


Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances in treatment and diagnosis have been made in recent years. In this review, we discuss potential biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome. The expression of these genes is tissue-specific. Tropomyosins are responsible for diverse cellular roles, most notably based upon their interplay with actin to maintain cellular processes, integrity and structure. Tropomyosins exhibit a large variety of splice forms, and altered isoform expression levels have been associated with cancer, including UBC. Notably, tropomyosin isoforms are detectable in urine, offering the potential for non-invasive diagnosis and risk-stratification. This review collates the basic knowledge on tropomyosin and its isoforms, and discusses their relationships with cancer-related phenomena, most specifically in UBC
Original languageEnglish
Article number1102
Number of pages14
JournalInternational Journal of Molecular Sciences
Issue number5
Publication statusPublished - 4 Mar 2019

Bibliographical note

Funding Information:
Funding: N Humayun-Zakaria’s research is funded by QEHB Charities.

Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.

Copyright 2019 Elsevier B.V., All rights reserved.


  • tropomyosin
  • TPM
  • urothelial bladder cancer


Dive into the research topics of 'Tropomyosins: potential biomarkers for Urothelial Bladder Cancer'. Together they form a unique fingerprint.

Cite this